This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR) (WATCH-TMVR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04494347
Recruitment Status : Recruiting
First Posted : July 31, 2020
Last Update Posted : February 1, 2024
Information provided by (Responsible Party):
Mohamad Adnan Alkhouli, Mayo Clinic

Brief Summary:
WATCH-TMVR (Watchman for Patients with Atrial Fibrillation Undergoing Transcatheter Mitral Valve) Clinical Trial have the main objective to assess the feasibility of combining clinically indicated MitraClip TMVR and Watchman LAAO in one setting.Mayo Clinic will be the data coordinating center for this trial, which will include up to 3 sites.

Condition or disease Intervention/treatment Phase
Nonvalvular Atrial Fibrillation Severe Degenerative Mitral Regurgitation Procedure: MitraClip TMVR and Watchman LAAO Not Applicable

Detailed Description:
Left atrial appendage closure using the Watchman device procedure is approved by the FDA for patients with nonvalvular atrial fibrillation who have an indication for oral anticoagulation to reduce stroke risk but who also have a rational to seek an alternative to long-term anticoagulation (e.g., recurrent bleeding, fall risk). Transcatheter mitral valve repair with the MitraClip device is approved by the FDA for patients with severe degenerative mitral regurgitation who are deemed to be at high-risk for valve surgery and patients with severe secondary MR despite optimal medical therapy. It is also anticipated that the device will soon be approved for patients with severe symptomatic functional mitral regurgitation based on the results of the COAPT trials. Atrial fibrillation is common in patients referred for TMVr. A recent study from the Mayo Clinic documented that up to 50% of patients undergoing TMVr might qualify for LAA based on their risk assessment. Both procedures are performed via a large bore femoral venous access, and utilize transseptal puncture, general anesthesia, and transesophageal echo guidance. Hence, combining the two procedures in one session might provide incremental benefit to those patients by avoiding the risk of repeated large-bore access, transseptal puncture, and general anesthesia. A limited number of case reports illustrated the safety and feasibility of a combined TMVr with LAAO when clinically indicated. Experience with combined TMVr/LAAO in the United States is limited, mostly due to the lack of supportive data and concerns about the incremental cost of the Watchman device that might not be covered by the Center for Medicare Services (CMS) per current guidelines.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a prospective multicenter registry of 25 patients who are planned to undergo TMVr with MitraClip and also have an indication for LAAO with the commercially available WATCHMAN device. All patients will undergo TMVr first under general anesthesia and transesophageal echo (TEE) guidance. At the conclusion of the TMVr procedure, the patient will undergo LAAO with the Watchman device using the same transseptal access the was obtained to perform the TMVr. Patients will receive oral anticoagulation with warfarin (or a direct anticoagulant) and subsequent antiplatelet therapy as per standard of care and outlined in protocol for 6 weeks. After 6 weeks, patients will have TEE done as per standard of care in addition to office visit and complete clinical and neurological evaluation. Continuation or discontinuation of oral anticoagulation will depend on the 45-day TEE findings. The anticipated duration of the Clinical Investigation will be 12 months.
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)
Actual Study Start Date : November 1, 2020
Estimated Primary Completion Date : January 2026
Estimated Study Completion Date : January 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment Group
This is not a randomized study. Patients who are clinically indicated for both procedures will be offered the option to enroll in this registry for a combined procedure. Otherwise, they will undergo TMVr and LAAO in two separate session as clinically indicated (standard of care).
Procedure: MitraClip TMVR and Watchman LAAO
The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.

Primary Outcome Measures :
  1. All-cause mortality rate [ Time Frame: 45 days post procedure ]
    Total number of Subject's Death

  2. All-cause mortality rate [ Time Frame: 1 Year post procedure ]
    Total number of Subject's Death

  3. Serious Adverse Events (SAEs) [ Time Frame: 45 days post procedure ]
    Total number of Subject's experiencing SAEs such Stroke, life-threatening or major bleeding.

  4. Serious Adverse Events (SAEs) [ Time Frame: 1 Year post procedure ]
    Total number of Subject's experiencing SAEs such Stroke, life-threatening or major bleeding.

Secondary Outcome Measures :
  1. SAEs related to the Study devices [ Time Frame: 1 Year ]
    Total number of the Subject's to experience SAEs as related to Watchman and the LAAO devices.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and Women ≥ 18 years of age;
  2. The patient has severe symptomatic mitral regurgitation meet criteria for the commercially available MitraClip;
  3. The patient also has documented paroxysmal, persistent, or permanent atrial fibrillation AND The patient meets the WATCHMAN labeling guidelines;
  4. The patient is eligible for short-term oral anticoagulation therapy with Warfarin or a direct oral anticoagulant;
  5. The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial;
  6. The patient is able and willing to return for required follow-up visits.

Exclusion Criteria:

  1. Mitral valve anatomy not deemed suitable for TMVr;
  2. Moderate to severe mitral stenosis (mean gradient >10 mmHg or MVA <1.5 cm2);
  3. Contraindication for short-term anticoagulation;
  4. The patient has intra-cardiac thrombus as visualized by TEE within 1 week prior to Watchman procedure;
  5. Prior occlusion of LAA;
  6. Implanted mechanical mitral valve;
  7. The patient requires long-term warfarin therapy due to:

    1. Secondary to conditions such as prior arterial embolism or other indications such as pulmonary embolism or deep vein thrombosis within the previous 6 months.
    2. The patient is in a hypercoagulable state.
  8. Exclude the patient if per medical record documentation the patient meets any of the following criteria: • Thrombosis occurring at under 40 years age • Idiopathic or recurrent VTE (venous thromboembolism • Thrombosis at an unusual site (cerebral veins, hepatic veins, renal veins, IVC, mesenteric veins) • Family history of VTE or of inherited prothrombotic disorder, recurrence/extension of thrombosis while adequately anti-coagulated;
  9. The patient is actively enrolled in another trial of a cardiovascular device or an investigational drug (post-market study and registries are acceptable);
  10. The patient is pregnant, or pregnancy is planned during the course of the investigation if patient is of child bearing potential;
  11. Any clinically significant medical condition or presence of any laboratory abnormality performed prior to randomization that is considered by the investigator to be clinically important and could interfere with the conduct of the study or not meeting procedure guidelines for WATCHMAN or TMVr with MitraClip;
  12. The patient has a life expectancy of less than one year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04494347

Layout table for location contacts
Contact: Mohamad Adnan (Mohamad) Alkhouli, MD 507-255-2504

Layout table for location information
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Carl Griffin    507-255-5690   
Contact: Anna Reed    (507) 255-0337   
Principal Investigator: Mohamad Alkhouli, MD         
Canada, Ontario
Ottawa Heart Institute Active, not recruiting
Ottawa, Ontario, Canada, K1Y 4W7
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Mohamad Adnan (Mohamad) Alkhouli, MD Mayo Clinic
Additional Information:
Layout table for additonal information
Responsible Party: Mohamad Adnan Alkhouli, Principal Investigator, Mayo Clinic Identifier: NCT04494347    
Other Study ID Numbers: 19-010047
First Posted: July 31, 2020    Key Record Dates
Last Update Posted: February 1, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Mitral Valve Insufficiency
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Heart Valve Diseases